(TherapeuticsMD) Shares of TherapeuticsMD rose more than 336% in premarket on Tuesday after agreeing to a merger acquisition at $10.00 a share by an affiliate of EW Healthcare Partners.
At the $10.00 per share all-cash transaction, the deal values TherapeuticsMD at a 367.3% premium to the stocks closing on May 27. The deal also carries a premium of 211.8% to TherapeuticsMD 30-day volume-weighted average share price on the same date of closing.
TXMD’s board of directors has already approved the deal, which carries a total enterprise value of about $177 million.
The tender offer for the acquisition will remain open for 20 business days but can be extended under certain circumstances.
Upon the closure of the transaction, TherapeuticsMD will be privately owned. The combination is expected to finalize on or before July 13, 2022.
NASDAQ: TXMD is up +336.92%.
